Key Takeaways from the TYK2 Inhibitors Market Report<\/p>\n
As per DelveInsight’s analysis, the total market size of TYK2 inhibitors\u00a0in the 7MM is expected to surge significantly by 2034.
\n The market size of SOTYKTU was USD 190 million in the US in 2024, with a 32% year-over-year increase.
\n The report provides the total potential number of patients in the indications, such as SLE, Crohn’s disease, Hidradenitis suppurativa, Psoriatic Arthritis, Dermatomyositis, and others.
\n Leading TYK2 inhibitor\u00a0companies, such as Priovant Therapeutics, Takeda, Alumis, Galapagos, Oncostellae, Neuron23, and others, are developing novel TYK2 inhibitors\u00a0that can be available in the TYK2 inhibitors\u00a0market in the coming years.\u00a0
\n Some of the key TYK2 inhibitors\u00a0in the pipeline include Brepocitinib, Zasocitinib, ESK-001, GLPG3667, OST-122, NEU-111, and others.
\n In March 2025, Alumis and Kaken Pharmaceutical entered into a collaboration and licensing agreement to develop, manufacture, and commercialize ESK-001 for dermatology indications in Japan, with the option to expand the license to include rheumatological and gastrointestinal diseases.
\n In December 2024, Bristol Myers Squibb announced results from the POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055) Phase III trials, which assessed the efficacy and safety of SOTYKTU (deucravacitinib) in adults with active psoriatic arthritis.<\/p>\n
Discover which indication is expected to grab the major TYK2 inhibitors market share @ TYK2 Inhibitors Market Report<\/a><\/p>\n TYK2 Inhibitors Market Dynamics<\/p>\n The market for TYK2 inhibitors is emerging as a dynamic and rapidly evolving segment within the broader immunology and inflammation therapeutics space. Unlike broader JAK inhibitors that often target multiple JAK subtypes and are associated with off-target effects and safety concerns, selective TYK2 inhibitors offer a more targeted approach, potentially minimizing adverse effects while maintaining efficacy. This selectivity is a key driver of pharmaceutical interest and investor confidence in this class of drugs.<\/p>\n Deucravacitinib, developed by Bristol Myers Squibb, is the first and most prominent TYK2 inhibitor to receive regulatory approval, having been cleared by the FDA for the treatment of moderate-to-severe plaque psoriasis. Its oral once-daily administration and favorable safety profile compared to JAK inhibitors have set a benchmark in the field, paving the way for other TYK2 inhibitors in clinical development. Several companies are actively advancing their own TYK2 candidates, targeting a broader range of autoimmune indications and hoping to capitalize on the differentiated profile of this class.<\/p>\n Market dynamics are being shaped not only by clinical progress but also by regulatory and payer scrutiny. As TYK2 inhibitors are closely related to JAK inhibitors, regulators have shown heightened vigilance regarding their safety, particularly around immunosuppression, cardiovascular events, and malignancies. However, early data from selective TYK2 inhibitors suggest they may avoid some of the black box warnings attached to JAK inhibitors, which could offer a competitive edge in terms of market access and physician preference. Nevertheless, long-term real-world data will be crucial to cement their positioning as safer alternatives.<\/p>\n Commercial uptake will also be influenced by competitive pressures from biologics and newer small molecules across different autoimmune disease indications. For instance, in psoriasis, TYK2 inhibitors compete against well-established biologics like IL-17 and IL-23 inhibitors, which have demonstrated high efficacy. However, the convenience of oral administration and lower manufacturing costs give TYK2 inhibitors a potential edge in less severe disease segments or in markets with limited access to biologics. Pricing strategies, payer negotiations, and inclusion in treatment guidelines will all play a vital role in determining the extent of market penetration.<\/p>\n TYK2 Inhibitors Treatment Market<\/p>\n Tyrosine kinase 2 inhibitors are being developed as effective therapies for a range of immune-mediated conditions, including psoriasis, psoriatic arthritis, hidradenitis suppurativa, inflammatory bowel disease (IBD), dermatomyositis, Crohn’s disease, systemic lupus erythematosus (SLE), ulcerative colitis, and others.<\/p>\n Currently, the only approved TYK2 inhibitor is Bristol-Myers Squibb’s SOTYKTU (deucravacitinib). SOTYKTU is a selective allosteric inhibitor that targets the regulatory domain of TYK2, a member of the Janus kinase family. By binding to this domain, SOTYKTU stabilizes the inhibitory interaction between the regulatory and catalytic domains of TYK2, leading to suppression of receptor-driven activation and downstream signaling through STAT proteins, as demonstrated in cellular assays.<\/p>\n TYK2 typically dimerizes with JAK1 to drive multiple cytokine signaling pathways and also partners with JAK2 in certain contexts. Although the exact mechanism by which TYK2 inhibition produces clinical benefit in moderate-to-severe plaque psoriasis remains unclear, SOTYKTU has received approval for use in adults with this condition who are eligible for systemic therapy or phototherapy.<\/p>\n Learn more about the TYK2 inhibitors\u00a0@ TYK2 Inhibitors Analysis<\/a><\/p>\n Key Emerging TYK2 Inhibitors and Companies<\/p>\n Several companies, including Priovant Therapeutics (brepocitinib), Alumis (ESK-001), Galapagos (GLPG366), Takeda (zasocitinib), and others, are engaged in the development of TYK2 inhibitors.<\/p>\n ESK-001\u00a0is a TYK2 inhibitor that blocks signaling from several cytokine receptors, including those for interleukin-23 (IL-23) and type 1 interferons. By targeting key pro-inflammatory pathways involved in the development of systemic lupus erythematosus (SLE), ESK-001 may help lower disease activity. The drug is currently undergoing evaluation in a Phase II clinical trial.<\/p>\n Priovant’s lead candidate, brepocitinib, is an oral, once-daily dual inhibitor of TYK2 and JAK1. Its selective inhibition of both pathways is designed to broadly suppress cytokine signaling associated with autoimmune conditions, including type I and type II interferons, IL-6, IL-12, and IL-23.<\/p>\n Priovant is advancing brepocitinib in multiple serious autoimmune indications. The drug is being tested in the VALOR Study, a fully enrolled registrational Phase III trial in dermatomyositis, with top-line data anticipated in 2025. In addition, Priovant has launched the Phase III CLARITY Study in non-infectious uveitis (NIU) following promising Phase II results from the NEPTUNE Study. A Phase II trial of brepocitinib in cutaneous sarcoidosis is also planned for 2025.<\/p>\n The anticipated launch of these emerging therapies are poised to transform the TYK2 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the TYK2 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n To know more about TYK2 inhibitors clinical trials, visit @ TYK2 Inhibitors Treatment<\/a><\/p>\n TYK2 Inhibitors Overview<\/p>\n TYK2, a member of the Janus kinase (JAK) family, plays a crucial role in pro-inflammatory signaling pathways within both the innate and adaptive immune systems. Its activation is thought to be key in driving cellular mechanisms linked to the onset and progression of autoimmune diseases. Unlike broader JAK inhibitors, selectively targeting TYK2 may lead to fewer side effects. TYK2 inhibitors are a class of drugs designed to block the activity of this specific enzyme, which is involved in immune responses and inflammation. By doing so, they aim to alleviate inflammation and its symptoms. These inhibitors are under investigation for their potential in treating several autoimmune conditions, such as psoriasis, psoriatic arthritis, inflammatory bowel disease (IBD), and others.<\/p>\n TYK2 Inhibitors Epidemiology Segmentation<\/p>\n The TYK2 inhibitors market report proffers epidemiological analysis for the study period 2020\u20132034 in the 7MM, segmented into:<\/p>\n Total Cases in Selected Indications for TYK2 inhibitors TYK2 Inhibitors Report Metrics<\/p>\n Details<\/p>\n Study Period<\/p>\n 2020\u20132034<\/p>\n TYK2 Inhibitors Report\u00a0Coverage<\/p>\n 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]<\/p>\n Key Indications Covered in the Report<\/p>\n SLE, Crohn’s disease, Hidradenitis suppurativa, Psoriatic Arthritis, Dermatomyositis, and others<\/p>\n Key TYK2 Inhibitor Companies<\/p>\n Priovant Therapeutics, Takeda, Alumis, Galapagos, Oncostellae, Neuron23, Bristol-Myers Squibb, and others<\/p>\n Key TYK2 Inhibitors<\/p>\n Brepocitinib, Zasocitinib, ESK-001, GLPG3667, OST-122, NEU-111, SOTYKTU, and others<\/p>\n Scope of the TYK2 Inhibitors\u00a0Market Report<\/p>\n TYK2 Inhibitors Therapeutic Assessment: TYK2 Inhibitors’ current marketed and emerging therapies Discover more about TYK2 inhibitors in development @ TYK2 Inhibitors Clinical Trials<\/a><\/p>\n Table of Contents<\/p>\n 1<\/p>\n Key Insights<\/p>\n 2<\/p>\n Report Introduction<\/p>\n 3<\/p>\n Executive Summary<\/p>\n 4<\/p>\n Key Events<\/p>\n 5<\/p>\n Market Forecast Methodology<\/p>\n 6<\/p>\n TYK2 Inhibitor Market Overview at a Glance in the 7MM<\/p>\n 6.1<\/p>\n Market Share (%) Distribution by Indication in 2024<\/p>\n 6.2<\/p>\n Market Share (%) Distribution by Indication in 2034<\/p>\n 7<\/p>\n TYK2 Inhibitor: Background and Overview<\/p>\n 7.1<\/p>\n Introduction<\/p>\n 7.2<\/p>\n Evolution of TYK2 Inhibitor<\/p>\n 7.3<\/p>\n Treatment<\/p>\n 8<\/p>\n Target Patient Pool<\/p>\n 8.1<\/p>\n Key Findings<\/p>\n 8.2<\/p>\n Assumptions and Rationale: 7MM<\/p>\n 8.3<\/p>\n Epidemiology Scenario in the 7MM<\/p>\n 8.3.1<\/p>\n Total Cases in Selected Indications for TYK2 Inhibitor in the 7MM<\/p>\n 8.3.2<\/p>\n Total Eligible Patient Pool in Selected Indications for TYK2 Inhibitor in the 7MM<\/p>\n 8.3.3<\/p>\n Total Treated Cases in Selected Indications for TYK2 Inhibitor in the 7MM<\/p>\n 8.4<\/p>\n The US<\/p>\n 8.5<\/p>\n EU4 and the UK<\/p>\n 8.6<\/p>\n Japan<\/p>\n 9<\/p>\n Marketed Therapies<\/p>\n 9.1<\/p>\n Key Cross Competition<\/p>\n 9.2<\/p>\n SOTYKTU (deucravacitinib): Bristol-Myers Squibb<\/p>\n 9.2.1<\/p>\n Product Description<\/p>\n 9.2.2<\/p>\n Regulatory Milestones<\/p>\n 9.2.3<\/p>\n Others Developmental Activities<\/p>\n 9.2.4<\/p>\n Clinical Trials Information<\/p>\n 9.2.5<\/p>\n Safety and Efficacy<\/p>\n List of drugs to be continued in the final report…<\/p>\n 10<\/p>\n Emerging Therapies<\/p>\n 10.1<\/p>\n Key Cross Competition<\/p>\n 10.2<\/p>\n Brepocitinib: Priovant Therapeutics<\/p>\n 10.2.1<\/p>\n Drug Description<\/p>\n 10.2.2<\/p>\n Others Developmental Activities<\/p>\n 10.2.3<\/p>\n Clinical Trials Information<\/p>\n 10.2.4<\/p>\n Safety and Efficacy<\/p>\n 10.2.5<\/p>\n Analyst’s View<\/p>\n 10.3<\/p>\n ESK-001: Alumis<\/p>\n List of drugs to be continued in the final report…<\/p>\n 11<\/p>\n TYK2 Inhibitor: the 7MM Analysis<\/p>\n 11.1<\/p>\n Key Findings<\/p>\n 11.2<\/p>\n Key Market Forecast Assumptions<\/p>\n 11.2.1<\/p>\n Cost Assumptions and Rebates<\/p>\n 11.2.2<\/p>\n Pricing Trends<\/p>\n 11.2.3<\/p>\n Analogue Assessment<\/p>\n 11.2.4<\/p>\n Launch Year and Therapy Uptakes<\/p>\n 11.3<\/p>\n Market Outlook<\/p>\n 11.4<\/p>\n Attribute Analysis<\/p>\n 11.5<\/p>\n Total Market Size of TYK2 Inhibitor in the 7MM<\/p>\n 11.6<\/p>\n The US Market Size<\/p>\n 11.6.1<\/p>\n Total Market Size of TYK2 Inhibitor in the US<\/p>\n 11.6.2<\/p>\n Market Size of TYK2 Inhibitor by Therapies in the US<\/p>\n 11.7<\/p>\n EU4 and the UK Market Size<\/p>\n 11.7.1<\/p>\n Total Market Size of TYK2 Inhibitor in EU4 and the UK<\/p>\n 11.7.2<\/p>\n Market Size of TYK2 Inhibitor by Therapies in EU4 and the UK<\/p>\n 11.8<\/p>\n Japan Market Size<\/p>\n 11.8.1<\/p>\n Total Market Size of TYK2 Inhibitor in Japan<\/p>\n 11.8.2<\/p>\n Market Size of TYK2 Inhibitor by Therapies in Japan<\/p>\n 12<\/p>\n Unmet Needs<\/p>\n 13<\/p>\n SWOT Analysis<\/p>\n 14<\/p>\n KOL Views<\/p>\n 15<\/p>\n Market Access and Reimbursement<\/p>\n 15.1<\/p>\n The US<\/p>\n 15.2<\/p>\n EU4 and the UK<\/p>\n 15.3<\/p>\n Japan<\/p>\n 16<\/p>\n Acronyms and Abbreviations<\/p>\n 17<\/p>\n Bibliography<\/p>\n Related Reports<\/p>\n JAK Inhibitors Market<\/a><\/p>\n JAK Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast \u2013 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors\u00a0companies, including Pfizer, AbbVie, Galapagos, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, among others.<\/p>\n Crohn’s Disease Market<\/a><\/p>\n Crohn’s Disease Market Insights, Epidemiology, and Market Forecast \u2013 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Crohn’s disease\u00a0companies, including RedHill Biopharma, Arena Pharmaceuticals, Merck, Teva Pharmaceutical, Pfizer, Agomab Therapeutics, Sanofi, Medibiofarma, Eli Lilly, Morphic Therapeutics, NImmune, Avobis Bio, Alimentiv, Abivax S.A., Roche, Mesoblast, Takeda, AstraZeneca,\u00a0among others.<\/p>\n Hidradenitis Suppurativa Market<\/a><\/p>\n Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast \u2013 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hidradenitis suppurativa companies, including Incyte Corporation, ACELYRIN, AbbVie, MoonLake Immunotherapeutics, Boehringer Ingelheim, Priovant Therapeutics, Eli Lilly, Incyte Corporation, Sanofi, Kymera Therapeutics, UNION Therapeutics, among others.<\/p>\n Systemic Lupus Erythematosus Market<\/a><\/p>\n Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast \u2013 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SLE companies, including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others.<\/p>\n About\u00a0DelveInsight<\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/p>\n Contact Us
\n Total Eligible Patient Pool in Selected Indications for TYK2 inhibitors
\n Total Treated Cases in Selected Indications for TYK2 inhibitors<\/p>\n
\n TYK2 Inhibitors\u00a0Market Dynamics: Conjoint Analysis of Emerging TYK2 Inhibitor\u00a0Drugs
\n Competitive Intelligence Analysis:\u00a0SWOT analysis and Market entry strategies
\n Unmet Needs, KOL’s views, Analyst’s views, TYK2 Inhibitors Market Access and Reimbursement<\/p>\n
Shruti Thakur
[email\u00a0protected]<\/a>
+14699457679<\/p>\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO44382&Transmission_Id=202508051731PR_NEWS_USPR_____IO44382&DateId=20250805\")
<\/p>\n","protected":false},"excerpt":{"rendered":"The TYK2 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing…\n","protected":false},"author":2,"featured_media":44219,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[3252,84,9459,24970,9460,8721,467,25926,13214,56,54,55],"class_list":["post-46816","post","type-post","status-publish","format-standard","has-post-thumbnail","category-markets","tag-biotechnology","tag-business","tag-delveinsight-business-research","tag-health-care-hospitals","tag-llp","tag-market-research-reports","tag-markets","tag-medical-pharmaceuticals","tag-pharmaceuticals","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/46816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=46816"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/46816\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/44219"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=46816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=46816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=46816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}